micafungin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antifungal antibiotics	1798	235114-32-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: mycamine micafungin micafungin sodium FK-463 FK463	A cyclic lipo-hexapeptide echinocandin antifungal agent that is used for the treatment and prevention of CANDIDIASIS. Molecular weight: 1270.28 Formula: C56H71N9O23S CLOGP: -1.99 LIPINSKI: 3 HAC: 32 HDO: 16 TPSA: 510.14 ALOGS: -3.77 ROTB: 18

Molecule

Description

Molfile Inchi Smiles

Synonyms:

mycamine
micafungin
micafungin sodium
FK-463
FK463

A cyclic lipo-hexapeptide echinocandin antifungal agent that is used for the treatment and prevention of CANDIDIASIS.

Molecular weight: 1270.28
Formula: C56H71N9O23S
CLOGP: -1.99
LIPINSKI: 3
HAC: 32
HDO: 16
TPSA: 510.14
ALOGS: -3.77
ROTB: 18

Drug dosage:

Dose	Unit	Route
0.10	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	1 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	6.30 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	0.21 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.17 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.00 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	16 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
March 16, 2005	FDA	FUJISAWA HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	201.23	25.45	135	6273	97532	50501184
Pre-engraftment immune reaction	170.31	25.45	29	6379	209	50598507
Human herpesvirus 6 infection	157.17	25.45	41	6367	2565	50596151
Encephalitis viral	145.68	25.45	35	6373	1562	50597154
Multiple organ dysfunction syndrome	114.17	25.45	74	6334	50263	50548453
Cytomegalovirus test positive	105.86	25.45	30	6378	2562	50596154
Acute graft versus host disease	93.33	25.45	30	6378	3928	50594788
Sepsis	84.98	25.45	94	6314	132831	50465885
Acute graft versus host disease in skin	84.15	25.45	26	6382	2992	50595724
Bacterial sepsis	79.56	25.45	26	6382	3586	50595130
Pneumonia fungal	78.88	25.45	27	6381	4293	50594423
Aplastic anaemia	77.27	25.45	31	6377	7672	50591044
Hepatic function abnormal	69.06	25.45	46	6362	32635	50566081
Aspergillus infection	66.86	25.45	27	6381	6794	50591922
Thrombotic microangiopathy	66.72	25.45	29	6379	8762	50589954
Cytomegalovirus viraemia	65.32	25.45	24	6384	4685	50594031
Mucormycosis	63.40	25.45	20	6388	2463	50596253
Engraft failure	60.91	25.45	13	6395	337	50598379
Septic shock	59.91	25.45	53	6355	57122	50541594
Gastrointestinal fungal infection	58.46	25.45	12	6396	256	50598460
Cytomegalovirus infection	57.62	25.45	33	6375	17929	50580787
Meningoencephalitis herpetic	55.73	25.45	15	6393	1057	50597659
Pyrexia	55.04	25.45	137	6271	380066	50218650
Bronchopulmonary aspergillosis	54.22	25.45	24	6384	7568	50591148
Off label use	53.67	25.45	156	6252	474270	50124446
Graft versus host disease	52.26	25.45	22	6386	6144	50592572
Sinus polyp	50.76	25.45	11	6397	307	50598409
Pathogen resistance	50.58	25.45	21	6387	5668	50593048
Product use in unapproved indication	49.67	25.45	67	6341	115752	50482964
Enterococcal sepsis	48.65	25.45	14	6394	1261	50597455
Respiratory failure	47.33	25.45	58	6350	91123	50507593
Weissella infection	47.20	25.45	7	6401	17	50598699
Liver abscess	46.53	25.45	16	6392	2577	50596139
Systemic mycosis	46.16	25.45	13	6395	1084	50597632
Platelet count decreased	42.76	25.45	58	6350	100668	50498048
Aspartate aminotransferase increased	42.73	25.45	51	6357	77947	50520769
Plasma cell leukaemia	42.58	25.45	12	6396	1003	50597713
Hypoalbuminaemia	42.40	25.45	22	6386	9838	50588878
Haemophagocytic lymphohistiocytosis	42.19	25.45	21	6387	8612	50590104
Systemic candida	41.60	25.45	15	6393	2775	50595941
Fatigue	41.53	25.45	19	6389	707582	49891134
Disseminated intravascular coagulation	40.79	25.45	26	6382	17109	50581607
Nasal abscess	40.53	25.45	8	6400	139	50598577
Biloma	40.02	25.45	7	6401	60	50598656
Enterobacter infection	39.20	25.45	13	6395	1875	50596841
Acute myeloid leukaemia recurrent	38.85	25.45	12	6396	1378	50597338
Fungaemia	38.39	25.45	13	6395	1999	50596717
Encephalitis fungal	37.62	25.45	6	6402	27	50598689
Arthralgia	36.39	25.45	6	6402	438696	50160020
Mucosal erosion	35.51	25.45	11	6397	1276	50597440
Alanine aminotransferase increased	34.67	25.45	49	6359	88310	50510406
Chronic graft versus host disease	33.89	25.45	13	6395	2854	50595862
Fungal infection	33.82	25.45	29	6379	29936	50568780
Cytokine release syndrome	33.54	25.45	18	6390	8616	50590100
Epstein-Barr virus associated lymphoproliferative disorder	32.57	25.45	11	6397	1678	50597038
Enterococcal infection	31.42	25.45	16	6392	6882	50591834
Trichosporon infection	30.83	25.45	7	6401	243	50598473
Liver disorder	30.29	25.45	30	6378	37192	50561524
Pain	30.27	25.45	18	6390	578885	50019831
Cryptosporidiosis infection	29.79	25.45	7	6401	283	50598433
Renal impairment	29.74	25.45	42	6366	75619	50523097
Acute respiratory distress syndrome	29.22	25.45	23	6385	21076	50577640
Drug ineffective for unapproved indication	29.04	25.45	23	6385	21258	50577458
Acute graft versus host disease in intestine	28.97	25.45	10	6398	1629	50597087
Aspergillus test positive	28.87	25.45	7	6401	324	50598392
Pleural effusion	28.79	25.45	43	6365	81411	50517305
Varicella zoster virus infection	28.40	25.45	11	6397	2478	50596238
Oral fungal infection	28.38	25.45	11	6397	2484	50596232
Mixed liver injury	28.20	25.45	12	6396	3439	50595277
White blood cell count decreased	27.05	25.45	51	6357	116671	50482045
Fall	26.83	25.45	5	6403	334927	50263789
Blood bilirubin increased	26.39	25.45	26	6382	32012	50566704
Dizziness	26.04	25.45	6	6402	346363	50252353
Post transplant lymphoproliferative disorder	25.93	25.45	12	6396	4192	50594524
Differentiation syndrome	25.85	25.45	8	6400	925	50597791

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	174.50	19.82	206	10237	112034	29452050
Acute graft versus host disease in skin	153.95	19.82	59	10384	4605	29559479
Aplastic anaemia	145.78	19.82	65	10378	7445	29556639
Multiple organ dysfunction syndrome	132.89	19.82	136	10307	62980	29501104
Bronchopulmonary aspergillosis	104.47	19.82	61	10382	12283	29551801
Aspergillus infection	102.20	19.82	57	10386	10524	29553560
Herpes simplex oesophagitis	100.27	19.82	20	10423	119	29563965
Disseminated intravascular coagulation	95.58	19.82	69	10374	19911	29544173
Graft versus host disease	93.35	19.82	52	10391	9576	29554508
Acute graft versus host disease in intestine	89.54	19.82	33	10410	2308	29561776
Cytomegalovirus viraemia	89.50	19.82	44	10399	6276	29557808
Acute graft versus host disease	86.83	19.82	42	10401	5782	29558302
Candida infection	80.73	19.82	56	10387	15169	29548915
Cystitis haemorrhagic	66.44	19.82	33	10410	4809	29559275
Trichosporon infection	65.45	19.82	19	10424	621	29563463
Respiratory failure	64.94	19.82	120	10323	97011	29467073
Mucormycosis	64.47	19.82	33	10410	5125	29558959
Cytomegalovirus test positive	64.40	19.82	29	10414	3394	29560690
Product use in unapproved indication	64.04	19.82	112	10331	86763	29477321
Fungal infection	62.57	19.82	46	10397	13639	29550445
Fungaemia	59.34	19.82	24	10419	2157	29561927
Pyrexia	57.08	19.82	226	10217	287396	29276688
Venoocclusive liver disease	55.40	19.82	33	10410	6884	29557200
Acute graft versus host disease in liver	55.40	19.82	20	10423	1318	29562766
Fatigue	54.48	19.82	22	10421	316799	29247285
Fusarium infection	53.19	19.82	18	10425	979	29563105
Pre-engraftment immune reaction	52.31	19.82	11	10432	88	29563996
Sepsis	50.79	19.82	137	10306	142545	29421539
Cytomegalovirus infection	48.69	19.82	50	10393	23165	29540919
Septic shock	46.50	19.82	81	10362	62479	29501605
Glomerulosclerosis	46.43	19.82	15	10428	705	29563379
Acute myeloid leukaemia recurrent	46.41	19.82	19	10424	1761	29562323
Human herpesvirus 6 infection	45.58	19.82	19	10424	1844	29562240
Chronic graft versus host disease	45.26	19.82	24	10419	4005	29560079
Staphylococcal sepsis	43.26	19.82	31	10412	8831	29555253
Enterococcal infection	42.85	19.82	30	10413	8238	29555846
Cytokine release syndrome	42.50	19.82	36	10407	13083	29551001
Systemic candida	41.28	19.82	20	10423	2760	29561324
Botulism	41.22	19.82	10	10433	160	29563924
Hepatic function abnormal	40.41	19.82	59	10384	39200	29524884
Dizziness	40.08	19.82	9	10434	189675	29374409
Encephalitis viral	39.79	19.82	15	10428	1117	29562967
Haemophagocytic lymphohistiocytosis	36.46	19.82	30	10413	10474	29553610
Systemic mycosis	34.10	19.82	14	10429	1307	29562777
Cholestatic liver injury	33.91	19.82	15	10428	1682	29562402
Rhinocerebral mucormycosis	32.68	19.82	9	10434	242	29563842
Graft versus host disease in gastrointestinal tract	32.67	19.82	18	10425	3240	29560844
Off label use	32.57	19.82	199	10244	300601	29263483
Pneumonia fungal	32.38	19.82	22	10421	5755	29558329
Geotrichum infection	31.69	19.82	10	10433	435	29563649
Kidney fibrosis	31.22	19.82	15	10428	2032	29562052
Immunosuppressant drug level increased	31.21	19.82	20	10423	4745	29559339
Fall	30.87	19.82	12	10431	177166	29386918
Cystitis viral	30.24	19.82	10	10433	506	29563578
Necrotising oesophagitis	30.13	19.82	10	10433	512	29563572
Drug ineffective	29.62	19.82	224	10219	362946	29201138
Graft versus host disease in skin	29.37	19.82	17	10426	3362	29560722
Candida sepsis	29.32	19.82	12	10431	1111	29562973
Drug resistance	29.18	19.82	37	10406	21503	29542581
Renal failure	29.08	19.82	100	10343	118499	29445585
Delayed graft function	29.03	19.82	14	10429	1913	29562171
Mucosal disorder	28.98	19.82	13	10430	1507	29562577
Bacteraemia	28.65	19.82	32	10411	16291	29547793
Myocardial infarction	28.32	19.82	3	10440	110293	29453791
Idiopathic pneumonia syndrome	28.27	19.82	8	10435	238	29563846
Platelet count decreased	28.09	19.82	91	10352	104581	29459503
Pseudomembranous colitis	27.85	19.82	15	10428	2582	29561502
Cerebral aspergillosis	27.14	19.82	12	10431	1344	29562740
Reactive gastropathy	26.71	19.82	7	10436	155	29563929
Thymus hypoplasia	26.50	19.82	7	10436	160	29563924
Lymphoid tissue hypoplasia	26.50	19.82	7	10436	160	29563924
Mucosal inflammation	26.22	19.82	43	10400	31552	29532532
Enterococcal sepsis	25.97	19.82	12	10431	1490	29562594
Functional gastrointestinal disorder	25.04	19.82	13	10430	2077	29562007
Liver disorder	24.71	19.82	39	10404	27710	29536374
Infection	24.57	19.82	71	10372	76680	29487404
Thrombotic microangiopathy	24.44	19.82	22	10421	8659	29555425
Engraft failure	24.11	19.82	8	10435	409	29563675
Product dose omission issue	23.79	19.82	3	10440	96380	29467704
Ophthalmic vein thrombosis	23.56	19.82	5	10438	42	29564042
Klebsiella infection	23.45	19.82	20	10423	7329	29556755
Bacterial toxaemia	22.32	19.82	6	10437	147	29563937
Tumour lysis syndrome	22.30	19.82	26	10417	13858	29550226
Antithrombin III decreased	22.22	19.82	7	10436	303	29563781
Weight decreased	22.02	19.82	13	10430	150892	29413192
Engraftment syndrome	21.98	19.82	9	10434	834	29563250
Alternaria infection	21.85	19.82	7	10436	320	29563764
Neurological symptom	21.71	19.82	14	10429	3356	29560728
Cerebral ventricle collapse	21.37	19.82	5	10438	68	29564016
Skin necrosis	21.01	19.82	16	10427	4996	29559088
Somnolence	20.76	19.82	4	10439	93951	29470133
Staphylococcal infection	20.58	19.82	37	10406	29203	29534881
Adenoviral haemorrhagic cystitis	20.42	19.82	7	10436	396	29563688
Blood bilirubin increased	20.27	19.82	40	10403	33853	29530231
Device related sepsis	20.23	19.82	12	10431	2483	29561601
Depression	20.19	19.82	3	10440	85144	29478940
Disseminated aspergillosis	20.12	19.82	7	10436	414	29563670
Drug-induced liver injury	20.06	19.82	31	10412	21624	29542460
Venoocclusive disease	20.03	19.82	12	10431	2527	29561557

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	326.74	20.43	308	15449	187349	64295626
Aplastic anaemia	218.36	20.43	93	15664	13827	64469148
Pre-engraftment immune reaction	207.10	20.43	40	15717	301	64482674
Multiple organ dysfunction syndrome	206.50	20.43	182	15575	101231	64381744
Human herpesvirus 6 infection	175.24	20.43	59	15698	4595	64478380
Encephalitis viral	168.93	20.43	49	15708	2331	64480644
Aspergillus infection	163.82	20.43	80	15677	16299	64466676
Acute graft versus host disease	146.79	20.43	62	15695	9022	64473953
Cytomegalovirus viraemia	145.87	20.43	65	15692	10763	64472212
Acute graft versus host disease in skin	131.86	20.43	53	15704	6802	64476173
Bronchopulmonary aspergillosis	129.88	20.43	72	15685	19013	64463962
Product use in unapproved indication	125.18	20.43	183	15574	176435	64306540
Mucormycosis	124.96	20.43	52	15705	7289	64475686
Sepsis	119.62	20.43	207	15550	230134	64252841
Disseminated intravascular coagulation	117.92	20.43	82	15675	32266	64450709
Graft versus host disease	107.59	20.43	57	15700	13756	64469219
Cytomegalovirus infection	103.26	20.43	80	15677	37119	64445856
Trichosporon infection	98.56	20.43	26	15731	866	64482109
Respiratory failure	95.82	20.43	154	15603	161029	64321946
Herpes simplex oesophagitis	94.97	20.43	20	15737	242	64482733
Pyrexia	93.73	20.43	324	15433	558320	63924655
Hepatic function abnormal	93.67	20.43	96	15661	64217	64418758
Cytomegalovirus test positive	92.85	20.43	38	15719	5106	64477869
Fungal infection	91.46	20.43	72	15685	34179	64448796
Fungaemia	89.52	20.43	34	15723	3751	64479224
Pneumonia fungal	87.67	20.43	43	15714	8834	64474141
Acute graft versus host disease in intestine	87.46	20.43	33	15724	3576	64479399
Septic shock	84.58	20.43	116	15641	105321	64377654
Fatigue	84.30	20.43	39	15718	748691	63734284
Candida infection	81.64	20.43	65	15692	31354	64451621
Systemic candida	78.26	20.43	34	15723	5295	64477680
Enterococcal infection	74.84	20.43	45	15712	13821	64469154
Platelet count decreased	69.64	20.43	137	15620	167574	64315401
Cytokine release syndrome	69.40	20.43	50	15707	20779	64462196
Systemic mycosis	66.45	20.43	24	15733	2299	64480676
Dizziness	63.13	20.43	14	15743	430149	64052826
Haemophagocytic lymphohistiocytosis	62.66	20.43	44	15713	17565	64465410
Acute myeloid leukaemia recurrent	62.22	20.43	24	15733	2760	64480215
Venoocclusive liver disease	60.60	20.43	35	15722	9980	64472995
Pathogen resistance	58.27	20.43	37	15720	12506	64470469
Meningoencephalitis herpetic	57.23	20.43	20	15737	1741	64481234
Arthralgia	56.27	20.43	19	15738	442241	64040734
Fall	54.63	20.43	17	15740	416809	64066166
Acute graft versus host disease in liver	54.21	20.43	19	15738	1668	64481307
Drug resistance	54.01	20.43	54	15703	35048	64447927
Enterococcal sepsis	53.96	20.43	21	15736	2473	64480502
Bacterial sepsis	53.10	20.43	29	15728	7428	64475547
Off label use	52.17	20.43	297	15460	632509	63850466
Cystitis haemorrhagic	51.35	20.43	29	15728	7927	64475048
Drug ineffective	50.01	20.43	363	15394	839884	63643091
Chronic graft versus host disease	49.15	20.43	26	15731	6250	64476725
Hypoalbuminaemia	49.00	20.43	38	15719	17636	64465339
Thrombotic microangiopathy	48.78	20.43	37	15720	16618	64466357
Pain	48.03	20.43	39	15718	553472	63929503
Fusarium infection	47.86	20.43	17	15740	1552	64481423
Blood bilirubin increased	47.13	20.43	64	15693	57489	64425486
Headache	46.31	20.43	37	15720	529430	63953545
Gastrointestinal fungal infection	46.19	20.43	12	15745	376	64482599
Engraft failure	45.23	20.43	13	15744	598	64482377
Bacteraemia	44.37	20.43	43	15714	26868	64456107
Disseminated aspergillosis	44.08	20.43	13	15744	655	64482320
Aspartate aminotransferase increased	43.92	20.43	93	15664	119695	64363280
Renal failure	43.92	20.43	120	15637	181568	64301407
Lymphoid tissue hypoplasia	43.39	20.43	12	15745	479	64482496
Staphylococcal sepsis	43.05	20.43	31	15726	12868	64470107
Cholestatic liver injury	42.96	20.43	20	15737	3659	64479316
Weissella infection	42.60	20.43	7	15750	17	64482958
Thymus hypoplasia	42.42	20.43	12	15745	521	64482454
Pneumonia	42.40	20.43	257	15500	559319	63923656
Tumour lysis syndrome	41.70	20.43	36	15721	19404	64463571
Acute respiratory distress syndrome	40.89	20.43	49	15708	38886	64444089
Sinus polyp	39.63	20.43	11	15746	445	64482530
Glomerulosclerosis	39.37	20.43	13	15744	952	64482023
Cerebral aspergillosis	39.28	20.43	15	15742	1678	64481297
Liver abscess	38.89	20.43	21	15736	5259	64477716
Mucosal inflammation	38.76	20.43	61	15696	62523	64420452
Candida sepsis	38.65	20.43	16	15741	2212	64480763
Pleural effusion	38.27	20.43	91	15666	126468	64356507
Malaise	38.12	20.43	25	15732	396222	64086753
Renal impairment	37.55	20.43	94	15663	134923	64348052
Botulism	37.40	20.43	10	15747	351	64482624
Delayed graft function	37.00	20.43	17	15740	3019	64479956
Neutrophil count decreased	36.87	20.43	67	15690	77129	64405846
Mucosal disorder	36.86	20.43	17	15740	3045	64479930
Alanine aminotransferase increased	36.80	20.43	95	15662	138936	64344039
Nasopharyngitis	36.65	20.43	3	15754	196070	64286905
Product dose omission issue	36.35	20.43	3	15754	194744	64288231
Cystitis viral	35.98	20.43	11	15746	627	64482348
Mixed liver injury	35.43	20.43	20	15737	5461	64477514
Pain in extremity	35.21	20.43	15	15742	303070	64179905
Immunosuppressant drug level increased	35.19	20.43	22	15735	7237	64475738
Necrotising oesophagitis	35.13	20.43	11	15746	679	64482296
White blood cell count decreased	34.94	20.43	101	15656	157736	64325239
Nasal abscess	34.71	20.43	8	15749	150	64482825
Dyspnoea	34.59	20.43	78	15679	718596	63764379
Peripheral swelling	34.54	20.43	5	15752	209148	64273827
Rhinocerebral mucormycosis	34.40	20.43	10	15747	479	64482496
Engraftment syndrome	33.72	20.43	12	15745	1101	64481874
Idiopathic pneumonia syndrome	33.25	20.43	10	15747	539	64482436
Asthenia	32.53	20.43	34	15723	428010	64054965
Graft versus host disease in gastrointestinal tract	32.33	20.43	19	15738	5593	64477382
Blast cell count increased	32.10	20.43	12	15745	1267	64481708
Geotrichum infection	32.05	20.43	11	15746	907	64482068
Cytomegalovirus enterocolitis	31.42	20.43	12	15745	1343	64481632
Staphylococcal infection	30.83	20.43	49	15708	50629	64432346
Bacterial infection	30.56	20.43	34	15723	24916	64458059
Graft versus host disease in skin	30.53	20.43	18	15739	5329	64477646
Adenovirus infection	30.25	20.43	20	15737	7235	64475740
Lymphocyte count decreased	29.95	20.43	43	15714	40656	64442319
Graft versus host disease in liver	29.92	20.43	12	15745	1529	64481446
Plasma cell leukaemia	29.83	20.43	12	15745	1541	64481434
Disseminated cryptococcosis	29.73	20.43	12	15745	1555	64481420
Alopecia	29.72	20.43	3	15754	165687	64317288
Acute lymphocytic leukaemia recurrent	29.62	20.43	16	15741	4010	64478965
Biloma	29.49	20.43	7	15750	150	64482825
Klebsiella infection	29.31	20.43	25	15732	13256	64469719
Oesophagitis	29.15	20.43	31	15726	21599	64461376
Liver disorder	28.97	20.43	49	15708	53302	64429673
Nephropathy toxic	28.90	20.43	28	15729	17486	64465489
Epstein-Barr virus infection	28.57	20.43	24	15733	12464	64470511
Enterobacter infection	28.06	20.43	15	15742	3681	64479294
Drug intolerance	27.77	20.43	6	15751	187986	64294989
Weight increased	27.37	20.43	9	15748	213339	64269636
Mucosal erosion	27.29	20.43	12	15745	1922	64481053
Depression	26.77	20.43	6	15751	183285	64299690
Pseudomembranous colitis	26.64	20.43	16	15741	4900	64478075
Toxicity to various agents	26.36	20.43	30	15727	363483	64119492
Acute myeloid leukaemia	26.30	20.43	33	15724	27430	64455545
Drug-induced liver injury	26.18	20.43	44	15713	47599	64435376
Hypokalaemia	26.00	20.43	77	15680	121826	64361149
Rash morbilliform	25.98	20.43	16	15741	5125	64477850
Blood urea increased	25.91	20.43	42	15715	44111	64438864
Neutropenic colitis	25.06	20.43	15	15742	4566	64478409
Device related infection	24.98	20.43	34	15723	30592	64452383
Neutropenia	24.79	20.43	120	15637	239504	64243471
Kidney fibrosis	24.72	20.43	13	15744	3088	64479887
Pruritus	24.64	20.43	24	15733	312376	64170599
Bacterial toxaemia	24.13	20.43	6	15751	157	64482818
Leukaemia recurrent	23.93	20.43	12	15745	2582	64480393
Chest pain	23.90	20.43	14	15743	235966	64247009
Nausea	23.86	20.43	105	15652	785695	63697280
Pseudomonal sepsis	23.38	20.43	15	15742	5157	64477818
Candida test positive	23.11	20.43	9	15748	1061	64481914
Drug ineffective for unapproved indication	23.06	20.43	33	15724	31100	64451875
Aspergillus test positive	22.85	20.43	8	15749	700	64482275
Drug hypersensitivity	22.85	20.43	15	15742	237800	64245175
Reactive gastropathy	22.66	20.43	7	15750	413	64482562
Blood pressure increased	22.63	20.43	7	15750	172545	64310430
Viral haemorrhagic cystitis	22.61	20.43	10	15747	1625	64481350
Gait disturbance	22.55	20.43	7	15750	172148	64310827
Hypersensitivity	22.35	20.43	10	15747	196442	64286533
Oral disorder	22.19	20.43	18	15739	8903	64474072
Oral fungal infection	22.06	20.43	12	15745	3049	64479926
Staphylococcal bacteraemia	21.85	20.43	19	15738	10336	64472639
Overdose	21.79	20.43	6	15751	159560	64323415
Pulmonary mucormycosis	21.78	20.43	8	15749	804	64482171
Gamma-glutamyltransferase increased	21.77	20.43	41	15716	48469	64434506
Pulmonary haemorrhage	21.71	20.43	21	15736	13088	64469887
Blood lactate dehydrogenase increased	21.53	20.43	33	15724	33045	64449930
Myocardial infarction	21.26	20.43	7	15750	165814	64317161
Functional gastrointestinal disorder	21.24	20.43	13	15744	4118	64478857
Hyperbilirubinaemia	21.14	20.43	26	15731	21179	64461796
Hypoxia	21.04	20.43	58	15699	88091	64394884
Cerebral ventricle collapse	20.44	20.43	5	15752	122	64482853

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J02AX05	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE Other antimycotics for systemic use
FDA CS	M0519359	Lipopeptides
FDA EPC	N0000175507	Echinocandin Antifungal
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000935	Antifungal Agents
CHEBI has role	CHEBI:35441	antiinfective agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Candidiasis of the esophagus	indication	20639004	DOID:13146
Disseminated candidiasis	indication	70572005
Candidal septicemia	indication	187022007
Candidemia	indication	432261003
Prevention of Disseminated Candidiasis	indication
Candida Peritonitis	indication
Oropharyngeal Candidiasis	off-label use
Intravascular hemolysis	contraindication	15601008
Kidney disease	contraindication	90708001	DOID:557
Liver function tests abnormal	contraindication	166603001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.09	acidic
pKa2	10.7	acidic
pKa3	12.91	acidic
pKa4	13.44	acidic
pKa5	13.52	acidic
pKa6	13.9	acidic
pKa7	13.91	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 100MG BASE/VIAL	MYCAMINE	ASTELLAS	N021506	June 27, 2006	RX	INJECTABLE	INTRAVENOUS	Dec. 20, 2022	TREATMENT OF CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES WITHOUT MENINGOENCEPHALITIS AND/OR OCULAR DISSEMINATION IN PEDIATRIC PATIENTS YOUNGER THAN 4 MONTHS OF AGE
EQ 50MG BASE/VIAL	MYCAMINE	ASTELLAS	N021506	March 16, 2005	RX	INJECTABLE	INTRAVENOUS	Dec. 20, 2022	TREATMENT OF CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES WITHOUT MENINGOENCEPHALITIS AND/OR OCULAR DISSEMINATION IN PEDIATRIC PATIENTS YOUNGER THAN 4 MONTHS OF AGE
EQ 100MG BASE/VIAL	MYCAMINE	ASTELLAS	N021506	June 27, 2006	RX	INJECTABLE	INTRAVENOUS	June 20, 2023	PEDIATRIC EXCLUSIVITY
EQ 50MG BASE/VIAL	MYCAMINE	ASTELLAS	N021506	March 16, 2005	RX	INJECTABLE	INTRAVENOUS	June 20, 2023	PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Beta-1,3-glucan synthase catalytic subunit 1	Enzyme		O13428_CANAX	INHIBITOR				CHEMBL	CHEMBL
Beta-1,3-glucan synthase	Unclassified		Q5AIC4_CANAL					WOMBAT-PK

External reference:

ID	Source
D02465	KEGG_DRUG
208538-73-2	SECONDARY_CAS_RN
4024920	VANDF
4024948	VANDF
C1120386	UMLSCUI
CHEBI:600520	CHEBI
CHEMBL457547	ChEMBL_ID
CHEMBL1237070	ChEMBL_ID
D000077551	MESH_DESCRIPTOR_UI
DB01141	DRUGBANK_ID
8069	INN_ID
R10H71BSWG	UNII
477468	PUBCHEM_CID
325887	RXNORM
19567	MMSL
334346	MMSL
66902	MMSL
d05487	MMSL
010714	NDDF
010715	NDDF
416127003	SNOMEDCT_US
416233001	SNOMEDCT_US
426226002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9361	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	ANDA	27 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9362	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	ANDA	27 sections
Mycamine	HUMAN PRESCRIPTION DRUG LABEL	1	0469-3211	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	NDA	27 sections
Mycamine	HUMAN PRESCRIPTION DRUG LABEL	1	0469-3211	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	NDA	27 sections
Mycamine	HUMAN PRESCRIPTION DRUG LABEL	1	0469-3211	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	NDA	27 sections
Mycamine	HUMAN PRESCRIPTION DRUG LABEL	1	0469-3250	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	NDA	27 sections
Mycamine	HUMAN PRESCRIPTION DRUG LABEL	1	0469-3250	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	NDA	27 sections
Mycamine	HUMAN PRESCRIPTION DRUG LABEL	1	0469-3250	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	NDA	27 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	25021-190	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	50 mg	INTRAVENOUS	ANDA	29 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	25021-191	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	100 mg	INTRAVENOUS	ANDA	29 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	42023-229	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	NDA	26 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	42023-230	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	NDA	26 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6119	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	ANDA	27 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6120	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	ANDA	27 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	63323-728	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	50 mg	INTRAVENOUS	ANDA	30 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	63323-729	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	100 mg	INTRAVENOUS	ANDA	30 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	63323-729	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	100 mg	INTRAVENOUS	ANDA	30 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	70594-036	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	ANDA	34 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	70594-037	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	ANDA	34 sections